Jun 172013
| ThromboGenics’ Jetrea receives NICE approval for eye condition treatment |
| Biopharmaceutical company ThromboGenics’ Jetrea has received approval from UK’s National Institute for Health and Care Excellence (NICE) in the treatment of some adults with vitreomacular traction (VMT), a rare eye condition… |
Ocriplasmin (trade name Jetrea) is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from theretina.[1]
Sorry, the comment form is closed at this time.